Mirum Pharmaceuticals Inc（MIRM）財務資料MIRMMirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. (MIRM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Livmarli, accounting for 73.0% of total sales, equivalent to $128.72M. Another important revenue stream is Bile Acid Medicines. Understanding this composition is critical for investors evaluating how MIRM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Mirum Pharmaceuticals, Inc. maintains a gross margin of 82.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -14.81%, while the net margin is -38.14%. These profitability ratios, combined with a Return on Equity (ROE) of -702.97%, provide a clear picture of how effectively MIRM converts its operational activities into shareholder value.

In the context of the broader market, MIRM competes directly with industry leaders such as ERAS and MANE. With a market capitalization of $5.58B, it holds a significant position in the sector. When comparing efficiency, MIRM's gross margin of 82.78% stands against ERAS's N/A and MANE's N/A. Such benchmarking helps identify whether Mirum Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Mirum Pharmaceuticals has demonstrated an increasing trend in total revenue, reaching 176,243,000 USD in Q2 2026, with a gross margin of 82.78% indicating strong profitability. However, net income remains negative, with a significant loss of -67,227,000 USD in the same quarter.